Cipher Pharmaceuticals (TSE:CPH) Shares Cross Above 50 Day Moving Average – Time to Sell?

Shares of Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of C$14.60 and traded as high as C$14.82. Cipher Pharmaceuticals shares last traded at C$14.74, with a volume of 6,877 shares trading hands.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Leede Financial cut Cipher Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 13th. Stifel Nicolaus decreased their price objective on Cipher Pharmaceuticals from C$19.00 to C$17.00 in a research note on Monday, November 11th.

Cipher Pharmaceuticals Trading Up 0.1 %

The company has a debt-to-equity ratio of 0.33, a current ratio of 11.18 and a quick ratio of 2.67. The firm has a market cap of C$377.20 million, a price-to-earnings ratio of 11.79 and a beta of 1.20. The business’s 50-day moving average price is C$14.60 and its two-hundred day moving average price is C$14.02.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last issued its quarterly earnings results on Thursday, November 7th. The company reported C$0.01 earnings per share for the quarter, missing the consensus estimate of C$0.03 by C($0.02). Cipher Pharmaceuticals had a net margin of 102.01% and a return on equity of 28.43%. The business had revenue of C$14.15 million during the quarter, compared to analyst estimates of C$13.37 million. Equities analysts expect that Cipher Pharmaceuticals Inc. will post 1.2907348 earnings per share for the current year.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.